Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor α

被引:0
|
作者
Kinoshita, Y [1 ]
Chen, S [1 ]
机构
[1] City Hope Natl Med Ctr, Beckman Res Inst, Dept Surg Res, Duarte, CA 91010 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aromatase plays a critical role in breast cancer development by converting androgen to estrogen. In this report, results are presented to demonstrate that estrogen, the product of aromatase, can up-regulate its expression. Estrogen receptor (ER) transient transfection experiments were performed using the SK-BR-3 breast cancer cell line, which is ER negative and expresses aromatase. When SK-BR-3 cells were transfected with the expression plasmid pCI-ERalpha, but not pCI-ERbeta, aromatase activity was elevated by 17beta-estradiol (E-2) in a dose-dependent manner. The E-2 induction could be enhanced by cotransfection with the coactivator GRIP and suppressed by antiestrogens such as tamoxifen and ICI 182,780. The aromatase activity in the ERalpha-transfected SK-BR-3 cells could also be induced by environmental chemicals that were known to have an estrogen-like activity. Using aromatase gene exon Is-specific reverse transcription-PCR, the level of promoter I.1-driven transcripts was found to be elevated in E-2-treated ERalpha-transfected cells. This suggested that E-2 induced aromatase expression through the up-regulation of promoter I.1. Using DNA deletion analysis of the 5'-flanking region of promoter I.1, the section between -300 and -280 bp upstream from exon I.1 was identified to be important for mediating E-2 induction. However, a direct binding of ERalpha to this 20-bp region could not be demonstrated. It was found that E-2 induction could be suppressed by the mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor, PD98059, and the epidermal growth factor receptor tyrosine kinase inhibitor, PD153035 hydrochloride. A significant induction of aromatase expression was also detected in ER-positive MCF-7 breast cancer cells after transfection with pCI-ERalpha and E-2 treatment. Furthermore, after ERalpha transfection and E2 treatment, the aromatase activity in Her-2-overexpressing MCF-7 cells was drastically higher than that of the wild-type MCF-7 cells. In addition, aromatase induction in MCF-7 cells could also be suppressed by PD153035 hydrochloride. These results suggest that E-2 up-regulates aromatase expression by a nongenomic action of ERalpha via cross-talk with growth factor-mediated pathways.
引用
收藏
页码:3546 / 3555
页数:10
相关论文
共 50 条
  • [1] Aromatase activity and CYP19 gene expression in breast cancers
    Sourdaine, P
    Mullen, P
    White, R
    Telford, J
    Parker, MG
    Miller, WR
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1996, 59 (02): : 191 - 198
  • [2] Estrogen Receptor α (ERα) Mediates Stimulatory Effects of Estrogen on Aromatase (CYP19) Gene Expression in Human Placenta
    Kumar, Premlata
    Kamat, Amrita
    Mendelson, Carole R.
    MOLECULAR ENDOCRINOLOGY, 2009, 23 (06) : 784 - 793
  • [3] Genetic variants of CYP19 (aromatase) and breast cancer risk
    V Nedelcheva Kristensen
    N Harada
    N Yoshimura
    E Haraldsen
    PE Lønning
    B Erikstein
    R Kåresen
    T Kristensen
    A-L Børresen-Dale
    Breast Cancer Research, 2 (Suppl 1)
  • [4] Genetic variants of CYP19 (aromatase) and breast cancer risk
    Kristensen, VN
    Harada, N
    Yoshimura, N
    Haraldsen, E
    Lonning, P
    Erikstein, B
    Kåresen, R
    Kristensen, T
    Borresen-Dale, AL
    ONCOGENE, 2000, 19 (10) : 1329 - 1333
  • [5] Genetic variants of CYP19 (aromatase) and breast cancer risk
    Vessela Nedelcheva Kristensen
    Nobuhiro Harada
    Noriko Yoshimura
    Ellen Haraldsen
    P E Lønning
    Bjørn Erikstein
    Rolf Kåresen
    Tom Kristensen
    Anne-Lise Børresen-Dale
    Oncogene, 2000, 19 : 1329 - 1333
  • [6] A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk
    Talbott, Kathryn E.
    Gammon, Marilie D.
    Kibriya, Muhammad G.
    Chen, Yu
    Teitelbaum, Susan L.
    Long, Chang-Min
    Gurvich, Irina
    Santella, Regina M.
    Ahsan, Habibul
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 111 (03) : 481 - 487
  • [7] A rare CYP19 (aromatase) variant may increase the risk of breast cancer
    Kristensen, VN
    Andersen, TI
    Lindblom, A
    Erikstein, B
    Magnus, P
    Borresen-Dale, AL
    PHARMACOGENETICS, 1998, 8 (01): : 43 - 48
  • [8] A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk
    Kathryn E. Talbott
    Marilie D. Gammon
    Muhammad G. Kibriya
    Yu Chen
    Susan L. Teitelbaum
    Chang-Min Long
    Irina Gurvich
    Regina M. Santella
    Habibul Ahsan
    Breast Cancer Research and Treatment, 2008, 111 : 481 - 487
  • [9] Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer
    Harris, RE
    Robertson, FM
    Abou-Issa, HM
    Farrar, WB
    Brueggemeier, R
    MEDICAL HYPOTHESES, 1999, 52 (04) : 291 - 292
  • [10] Estrogen-Related Receptor γ (ERRγ) Mediates Oxygen-Dependent Induction of Aromatase (CYP19) Gene Expression during Human Trophoblast Differentiation
    Kumar, Premlata
    Mendelson, Carole R.
    MOLECULAR ENDOCRINOLOGY, 2011, 25 (09) : 1513 - 1526